When a company fires 600 people selling two of its branded drugs, you can frame it two ways. AstraZeneca wants you to pick the optimistic one.
On November 13, Bloomberg reported that AstraZeneca had cut about 600 positions from its US respiratory and immunology commercial teams as part of a three-year cost-savings programme the company unveiled in October. AstraZeneca has said the programme would incur up to $2 billion in one-time restructuring costs and deliver $1.5 billion in annualised pre-tax run-rate benefits, with savings largely reinvested into the pipeline. Bloomberg also reported AstraZeneca pulled back its partnership with contract sales organization Syneos Health in the US. Management’s line is consistent: this is a reallocation, not a retreat. The savings go into the pipeline. The story gets better from here.
But the numbers underneath that framing deserve a harder look.
What the Drug Sales Actually Say
After an FDA label expansion in April to include maintenance treatment of asthma, Breztri’s US sales in the third quarter increased only 2% year over year to $170 million. That is a thin return on a significant regulatory win. Airsupra performed worse, with $42 million in US sales in Q3, down 3% year over year. So the two drugs that just lost their dedicated sales force were already losing momentum before the cuts arrived.
By scaling back commercial headcount in a competitive respiratory and immunology landscape dominated by rivals like GSK’s Trelegy and Sanofi and Regeneron’s Dupixent, AstraZeneca is wagering that incremental R&D investment will yield superior shareholder returns compared to additional marketing spend. That is a defensible bet in theory. The problem is the competitive dynamics make it a risky one in practice.
Dupixent generated net sales of €9.324 billion in the first half of 2026, up 27.5% year over year on a reported basis. GSK’s Specialty Medicines segment posted 14% growth at constant exchange rates in the first half of 2026. Both rivals are leaning in. AstraZeneca is stepping back.
The Cleaner Story Argument
There is a legitimate case for AZN shares here, and it does not really rest on Breztri or Airsupra. Breztri still grew 16% at constant exchange rates to $1.073 billion across the first nine months of 2026, showing global traction even as the US slows. The bigger argument is that management is making a deliberate choice to stop throwing money at a maturing franchise and redirect it toward what actually moves the stock.
AstraZeneca has pointed to a deep late-stage slate, and in its Q3 update CEO Pascal Soriot said the company had reported 12 positive Phase III programme readouts with a collective peak-year revenue potential well in excess of $10 billion. At constant currencies, AstraZeneca said total revenue grew 7% year on year in Q3 and core EPS rose 14%, while reiterating full-year guidance and describing the three-year cost programme as a way to redeploy resources and fund the pipeline.
RBC Capital raised its price target on AstraZeneca shares to GBP 152.50 from GBP 145.00 while maintaining an Outperform rating. Nordea moved AstraZeneca from Sell to Buy and lifted its target to SEK 1,900, saying it expects investor attention to shift toward the cardiovascular pipeline.
What Could Go Wrong
Cutting sales staff is one thing. Winning back lost ground in respiratory is harder. Bloomberg’s reporting suggested the moves may not be the company’s last, which means the restructuring has further to run and execution risk compounds with each round. Meanwhile, Dupixent is not standing still. Its maker keeps stacking new indications while AZN is thinning out the team selling into the same disease categories.
Valuation views remain divided because pipeline growth must offset patent expiries, pricing pressure, and clinical risks. At roughly 17 times forward earnings, the stock prices in a lot of pipeline success that still needs to arrive.
The Bottom Line
AstraZeneca is making a coherent argument: Breztri and Airsupra do not need 600 more salespeople, they need better drugs behind them. If the pipeline delivers, this restructuring looks like discipline. If late-stage programs disappoint, cutting the commercial team that was at least generating some revenue will look like the wrong trade. For buyers today, AZN is a pipeline bet dressed up as a cost story. That is worth owning with clear eyes, not confusion about what changed.
